December 16, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is looking into new side effect risks for a batch of medicines including Novartis Pharma’s anti-IL-17 antibody Cosentyx (secukinumab) and Astellas Pharma’s SGLT2 inhibitor Suglat (ipragliflozin), a move likely to trigger a label...read more